Fosun International posted a sharp recovery in its first-half FY26 results, with net profit attributable to parent owners rising 160.3% year-on-year to RMB1.72 billion. The conglomerate also reported total revenue of RMB86.96 billion, driven by a strategic shift toward its core insurance and pharmaceutical businesses.

The results presentation, held in Hong Kong on August 28, 2026, marked the company’s return to the city for such an event after six years. Leadership highlighted that these figures reflect the success of recent strategic adjustments aimed at strengthening the group’s foundation.

Financial Performance and Revenue Mix

The group’s financials show a distinct pivot toward international markets. Overseas revenue reached RMB49.16 billion, constituting 56.5% of total revenue. This indicates that more than half of Fosun’s income now originates outside China, underscoring the effectiveness of its globalization strategy.

What the Numbers Show

The divergence between stable overall revenue and the significant surge in net profit suggests improved operational efficiency or margin expansion within core segments. With four core companies—Fosun Pharma, Yuyuan, Fidelidade, and Tourism—accounting for 73.5% of total revenue, the group has successfully consolidated its earnings base around high-performing assets rather than dispersed holdings.

Strategic Focus on Core Industries

Chairman Guo Guangchang described the period as one of "repairing the roof on a sunny day," emphasizing foundational strength over rapid, unchecked expansion. The integration of the insurance business with other competitive industries is now viewed as a key pathway for future profitability.

Co-Chairman Wang Qunbin noted that the group remains committed to streamlining operations to achieve investment-grade credit status. The focus is squarely on long-termism and navigating economic cycles through customer-centric innovation.

Innovation and Global Operations

Investment in technology innovation rose 16.7% year-on-year to RMB4.2 billion in the first half of 2026. Co-CEO Chen Qiyu highlighted advancements in pharmaceutical platforms, including monoclonal antibodies and CAR-T therapies, targeting solid tumors and immunology.

The strategy involves building a globally integrated operating system. Co-CEO Xu Xiaoliang outlined a two-sided globalization approach: leveraging global R&D and manufacturing (Side A) while enhancing global marketing and service networks (Side B) to improve brand penetration worldwide.

Fosun International Limited (HKEX: 00656) has received three awards from the Global Banking and Finance Review, a leading British financial magazine, recognizing its achievements in sustainable development, corporate social responsibility (CSR), and brand influence in Asia. Announced on Aug. 6, 2026, the awards underscore the company’s progress in executing its sustainability strategy and strengthening corporate governance while maintaining transparent operations.

The Hong Kong-based conglomerate was honored with the "ESG & Sustainability Awards – Best Sustainable Development Company Asia 2026," "CSR Awards – Best CSR Company Asia 2026," and "Brand of the Year Awards – Holding Group Brand of the Year Asia 2026." The judging panel emphasized that Fosun’s recognition reflects balanced development and outstanding performance, noting its ability to align commercial value with social value as a reference model for companies in Asia and globally.

ESG Ratings and Recognition

Fosun’s environmental, social, and governance performance has seen significant milestones in 2026. The company achieved an upgrade to the highest MSCI ESG rating of AAA, marking a five-year progression from an AA rating received in 2021. This upgrade indicates that Fosun’s management standards have reached a leading position among global peers. Additionally, its FTSE Russell ESG score rose to 4.2 out of a maximum of 5, securing inclusion in the FTSE4Good Index Series for the fifth consecutive time.

Fosun was also included in S&P Global’s Sustainability Yearbook 2026 and ranked in the top 1% of the Sustainability Yearbook (China Edition) 2026 for the third consecutive year. Other recognitions include the "Certificate of Excellence in Environmental, Social and Governance Reporting" from the Hong Kong Management Association and "Best ESG Company Hong Kong" from Financial Derivative magazine.

Corporate Social Responsibility Initiatives

The company’s CSR efforts are driven by the Fosun Foundation, established in 2012, which focuses on global emergency relief, rural revitalization, healthcare, and education. A key initiative is the Rural Doctors Program, launched in 2017, which has supported 25,000 rural doctors and benefited 3 million rural families. The program was selected as one of the UN Global Compact’s "20 Cases of Private Sector’s Sustainable Development in China for 20 Years."

In Q2 2026, Fosun launched the "AI Rural Doctor Assistant 2.0," which adds intelligent interpretation of lab and physical examination reports. The tool has been rolled out to 25,000 rural doctors, achieving a user satisfaction rate of 92%. During a recent visit to Guangchang County, Jiangxi Province, Chairman Guo Guangchang reaffirmed the company’s commitment to philanthropy, stating that supporting rural doctors reflects Fosun’s original aspiration.

Innovation and Healthcare Impact

Fosun continues to integrate AI into its core businesses, including pharmaceuticals and tourism. Henlius, part of Fosun’s health portfolio, utilized an AI-powered protein drug design platform to increase the binding affinity of a core project molecule by more than 20 times in three months. In tourism, Fosun Tourism Group launched the AI G.O intelligent system to digitize service experiences.

In pharmaceuticals, Fosun Pharma’s HANSIZHUANG, the world’s first monoclonal antibody targeting PD-1 approved for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), has been approved for marketing in over 40 countries and regions. HLX22 received Orphan Drug Designation approvals from both the US Food and Drug Administration (FDA) and the European Commission (EC) for gastric cancer. As of the end of 2025, Fosun Pharma’s artesunate for injection had saved more than 88 million patients with severe malaria worldwide, with more than 440 million vials supplied globally.